Latest filings (excl ownership)
6-K
Immutep successfully completes institutional placement and institutional component of entitlement offer
5 Jun 24
6-K
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
4 Jun 24
6-K
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003
15 May 24
6-K
Positive Initial Clinical Data Reported from Immutep’s Efti
2 May 24
6-K
Immutep Quarterly Activities Report & Appendix 4C
30 Apr 24
6-K
Immutep Announces Positive Preliminary Topline Results from
24 Apr 24
6-K
Immutep Appoints Leading Research Institute to Conduct
18 Apr 24
6-K
Immutep Announces First Clinical Data from 90mg Dosing of Efti
6 Mar 24
6-K
Half-Year Financial Report
29 Feb 24
6-K
Immutep Quarterly Activities Report & Appendix 4C
30 Jan 24
6-K
Immutep Receives Constructive Regulatory Feedback on TACTI-004
21 Dec 23
6-K
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
7 Dec 23
6-K
Current report (foreign)
9 Nov 23
6-K
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
6 Nov 23
6-K
Immutep Announces New Biomarker Data from TACTI-002 Phase II
3 Nov 23
6-K
Immutep Quarterly Activities Report & Appendix 4C
31 Oct 23
6-K
Immutep receives ~A$1.13 million R&D Tax Incentive
25 Oct 23
6-K
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial
24 Oct 23
20-F
2023 FY
Annual report (foreign)
24 Oct 23
6-K
Current report (foreign)
24 Oct 23
6-K
Immutep Announces Publication of Abstracts at ESMO Congress 2023
16 Oct 23
6-K
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
21 Sep 23
6-K
Immutep Receives Positive Scientific Advice from European Medicines Agency
2 Aug 23
6-K
Immutep Quarterly Activities Report & Appendix 4C
31 Jul 23
6-K
Current report (foreign)
28 Jul 23
6-K
Immutep Secures Third United States Patent for Eftilagimod Alpha
27 Jun 23
6-K
Current report (foreign)
20 Jun 23
6-K
Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous
5 Jun 23
6-K
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
2 Jun 23
6-K
Current report (foreign)
30 May 23
6-K
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
26 May 23
6-K
Current report (foreign)
25 May 23
6-K
Immutep Announces Promising New Clinical Data from Triple Combination
24 May 23
6-K
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial
17 May 23
6-K
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development
16 May 23
EFFECT
Notice of effectiveness
8 May 23
CORRESP
Correspondence with SEC
3 May 23
6-K
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating
2 May 23
UPLOAD
Letter from SEC
2 May 23
6-K
Immutep Quarterly Activities Report & Appendix 4C
28 Apr 23